GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » ROA %

MindBio Therapeutics (XCNQ:MBIO) ROA % : 132.36% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. MindBio Therapeutics's annualized Net Income for the quarter that ended in Mar. 2024 was C$0.27 Mil. MindBio Therapeutics's average Total Assets over the quarter that ended in Mar. 2024 was C$0.21 Mil. Therefore, MindBio Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was 132.36%.

The historical rank and industry rank for MindBio Therapeutics's ROA % or its related term are showing as below:

XCNQ:MBIO' s ROA % Range Over the Past 10 Years
Min: -780.22   Med: -539.85   Max: -372.43
Current: -780.22

During the past 3 years, MindBio Therapeutics's highest ROA % was -372.43%. The lowest was -780.22%. And the median was -539.85%.

XCNQ:MBIO's ROA % is ranked worse than
98.45% of 1546 companies
in the Biotechnology industry
Industry Median: -35.425 vs XCNQ:MBIO: -780.22

MindBio Therapeutics ROA % Historical Data

The historical data trend for MindBio Therapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics ROA % Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
ROA %
- -707.26 -372.43

MindBio Therapeutics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only -129.03 -1,762.79 -155.24 -77.01 132.36

Competitive Comparison of MindBio Therapeutics's ROA %

For the Biotechnology subindustry, MindBio Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MindBio Therapeutics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's ROA % falls into.



MindBio Therapeutics ROA % Calculation

MindBio Therapeutics's annualized ROA % for the fiscal year that ended in Jun. 2023 is calculated as:

ROA %=Net Income (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=-3.823/( (1.453+0.6)/ 2 )
=-3.823/1.0265
=-372.43 %

MindBio Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 is calculated as:

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0.272/( (0.134+0.277)/ 2 )
=0.272/0.2055
=132.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data. ROA % is displayed in the 30-year financial page.


MindBio Therapeutics  (XCNQ:MBIO) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=0.272/0.2055
=(Net Income / Revenue)*(Revenue / Total Assets)
=(0.272 / 1.536)*(1.536 / 0.2055)
=Net Margin %*Asset Turnover
=17.71 %*7.4745
=132.36 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


MindBio Therapeutics ROA % Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


MindBio Therapeutics (XCNQ:MBIO) Business Description

Traded in Other Exchanges
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.

MindBio Therapeutics (XCNQ:MBIO) Headlines

From GuruFocus